Clinical Trial Update: Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating AsiDNA, a DNA repair inhibitor, in combination with PARP inhibitors for relapsed platinum-sensitive ovarian cancer previously treated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• AsiDNA (AsiDNA)
• PARP inhibitors

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: TERMINATED